

Resource Summary Report

Generated by [dkNET](#) on Sep 8, 2026

FITC anti-human CD45

RRID:AB_2562050

Type: Antibody

Proper Citation

BioLegend Cat# 304038, RRID:AB_2562050

Antibody Information

URL: http://antibodyregistry.org/AB_2562050

Proper Citation: BioLegend Cat# 304038, RRID:AB_2562050

Target Antigen: CD45

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: FITC anti-human CD45

Description: This monoclonal targets CD45

Target Organism: human

Clone ID: Clone HI30

Antibody ID: AB_2562050

Vendor: BioLegend

Catalog Number: 304038

Alternative Catalog Numbers: 304054, 304006, 304005

Record Creation Time: 20231110T035226+0000

Record Last Update: 20260829T213022+0000

Ratings and Alerts

No rating or validation information has been found for FITC anti-human CD45.

No alerts have been found for FITC anti-human CD45.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 16 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Moret RA, et al. (2026) Modelling the Colorectal Cancer Immune Microenvironment Using Air-Liquid Interface Organoids for Personalised Therapeutic Evaluation. *Cirugia espanola*, 800285.

Zhang SW, et al. (2026) Sensory neurons drive immune exclusion by stimulating a dense extracellular matrix in the breast cancer tumor microenvironment. *Cell*, 189(4), 1039.

Li F, et al. (2026) Ferritin aggregation cell engager for CAR T avidity engineering against refractory leukemias. *Cell*, 189(7), 1942.

Tichy ED, et al. (2026) Myogenic dysregulation underlies tongue overgrowth in Beckwith-Wiedemann syndrome. *bioRxiv : the preprint server for biology*.

Wang H, et al. (2026) Targeting TMED4 enhances CD8+ T cell function and CAR T cell efficacy in solid tumors through the IRE1?-autophagy axis. *Science advances*, 12(24), eaee0517.

Yang W, et al. (2025) Impaired mitochondrial metabolism is a critical cancer vulnerability for MYC inhibitors. *Science advances*, 11(29), eadw5228.

Wang Y, et al. (2025) AGO2 mediates immunotherapy failure via suppressing tumor IFN-gamma response-dependent CD8+ T cell immunity. *Cell reports*, 44(4), 115445.

Braun LM, et al. (2025) Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity. *Cancer cell*, 43(2), 269.

Malmström E, et al. (2025) Human proteome distribution atlas for tissue-specific plasma proteome dynamics. *Cell*, 188(10), 2810.

Kulkarni AJ, et al. (2025) L-Phenylalanine is a metabolic checkpoint of human Th2 cells. *Cell reports. Medicine*, 6(12), 102466.

Bandyopadhyay S, et al. (2024) Mapping the cellular biogeography of human bone marrow niches using single-cell transcriptomics and proteomic imaging. *Cell*, 187(12), 3120.

Yoshikawa T, et al. (2024) Development of a chimeric cytokine receptor that captures IL-6 and enhances the antitumor response of CAR-T cells. *Cell reports. Medicine*, 5(5), 101526.

Wang Y, et al. (2024) Venetoclax acts as an immunometabolic modulator to potentiate adoptive NK cell immunotherapy against leukemia. *Cell reports. Medicine*, 5(6), 101580.

Gutierrez E, et al. (2023) An optimized IL-12-Fc expands its therapeutic window, achieving strong activity against mouse tumors at tolerable drug doses. *Med (New York, N.Y.)*, 4(5), 326.

Sureshchandra S, et al. (2023) Multimodal profiling of term human decidua demonstrates immune adaptations with pregravid obesity. *Cell reports*, 42(7), 112769.

Liu X, et al. (2022) CD16+ fibroblasts foster a trastuzumab-refractory microenvironment that is reversed by VAV2 inhibition. *Cancer cell*, 40(11), 1341.